Clinical Trial Search

Phase 3 N=91 Immunogenicity and Safety of a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine in Children

Meningococcal Infections

Primary: Antibody Titers Measured by Serum Bactericidal Assay Using Human Complement (hSBA) Against Meningococcal Serogroups A, C, Y, and W Before a Booster Dose of MenACYW…

Sanofi Pasteur, a Sanofi Company Results Jun 2020 0.0% serious AE View details

Phase 3 N=810 Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine

Meningitis · Meningococcal Meningitis · Meningococcal Infections

Primary: Percentage of Participants With Seroresponse to Meningococcal Serogroups A, C, Y, and W Following Vaccination With Either MenACYW Conjugate Vaccine or Menactra® Vaccine…

Sanofi Pasteur, a Sanofi Company Results Jun 2020 1.1% serious AE View details

Phase 3 N=710 A Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures

Partial-onset Seizures

Primary: Core Phase: Percent Change in Seizure Frequency (For All Partial Seizures) Per 28 Days in the Randomization Phase Relative to Pre-randomization Phase (Baseline)…

Eisai Co., Ltd. Results Jun 2020 10.7% serious AE View details

Phase 3 N=24 A Randomized Controlled Trial of Cognitive Remediation and D-cycloserine for Individuals With Bipolar Disorder

Bipolar Disorder

Primary: Change From Baseline in Cognitive Functioning — 10.90; 7.12 T-Scores

University of Arizona Results Jun 2020 0.0% serious AE View details

Phase 3 N=656 A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs

Rheumatoid Arthritis (RA)

Primary: Change From Baseline in Disease Activity Score (DAS) 28 C-Reactive Protein (CRP) at Week 12 (Non-inferiority) — -2.52; -2.00 units on a scale — p=< 0.001

AbbVie Results Jun 2020 13.5% serious AE View details

Phase 3 N=766 Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy

Epilepsy

Primary: Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) — 83.9 Percentage of participants

UCB BIOSCIENCES, Inc. Results Jun 2020 18.3% serious AE View details

Phase 3 N=147 BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity

Crohn Disease

Primary: Percentage of Patients With a Clinical Response (CDAI Decrease of ≥70 Compared With Baseline) at Week 4 — 88.0; 93.1 Percentage of participants

Boehringer Ingelheim Results Jun 2020 8.5% serious AE View details

Phase 3 N=119 Alternatives for Reducing Tics in Tourette Syndrome (TS): A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents

Tourette Syndrome

Primary: Change From Baseline in the TTS of the YGTSS at Week 12 — -9.1; -8.4 units on a scale — p=0.692

Teva Branded Pharmaceutical Products R&D, Inc. Results Jun 2020 0.0% serious AE View details

Phase 3 N=213 Safety of Dabigatran Etexilate in Blood Clot Prevention in Children

Venous Thromboembolism · Secondary Prevention

Primary: Event-free Probability of Recurrence of Venous Thromboembolism (VTE) at 6 and 12 Months — 1.000; 1.000; 0.979; 1.000 Probability

Boehringer Ingelheim Results Jun 2020 14.1% serious AE View details

Phase 3 N=1,351 Stepping Stones and Creating Futures Intervention Trial

IPV · Sexual Violence

Primary: Any Past Year Physical Intimate Partner Violence Perpetration (Men) and Experience (Women) — 134; 86; 155; 118 Participants — p==0.686

University of KwaZulu Results Jun 2020 0.4% serious AE View details

Phase 3 N=1,009 A Study to Evaluate the Safety and Clinical Study of Azelaic Acid Gel 15% in Patients With Moderate Facial Rosacea

Rosacea

Primary: Percent Change From Baseline to Week 12 in the Inflammatory (Papules and Pustules) Lesion Counts. — -66.96; -68.62; -38.64 Percent change in lesion counts

Actavis Inc. Results Jun 2020 0.1% serious AE View details

Phase 3 N=630 Clinical Endpoint Study of Ivermectin 1% Cream

Moderate to Severe Papulopustular Rosacea

Primary: Percent Change From Baseline to Week 12 in the Number of Inflamed (Papules/Pustules) Lesions of Rosacea. — -64.87; -64.87; -55.04 percentage of change from baseline…

Actavis Inc. Results Jun 2020 0.0% serious AE View details

Phase 3 N=743 Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO)

HIV Infections

Primary: Percentage of Participants With Virologic Failure Endpoint as Per Food and Drug Administration (FDA) Snapshot Category at Week 48 — 0.3; 0.5 Percentage of participants

ViiV Healthcare Results Jun 2020 11.9% serious AE View details

Phase 3 N=58 PRecision Interventions for SMoking in the SCCS

Tobacco Use Cessation

Primary: Intervention Feasibility: Ability to Retain Participants — 19; 19; 20; 18 Participants

Vanderbilt University Medical Center Results Jun 2020 0.0% serious AE View details

Phase 3 N=111 A Long-term Safety Study of Fixed Dose Combination Therapy Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate in Japanese Subjects With Asthma

Asthma

Primary: Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs) — 23; 7; 32; 1 Participants

GlaxoSmithKline Results May 2020 2.7% serious AE View details